Lifevantage Corporation

Lifevantage Corporation

LFVN

Get informed when a big investor buys or sells

+ Follow
Market Cap$99.29M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Lifevantage CorporationLifevantage Corporation17.32.29%21%0.50.3
$5.00

Target Price by Analysts

39.9% downsideLifevantage Target Price DetailsTarget Price
$14.64

Current Fair Value

76% upside

Undervalued by 76% based on the discounted cash flow analysis.

Share Statistics

Market cap$99.29 Million
Enterprise Value$97.01 Million
Dividend Yield$0.18 (2.29%)
Earnings per Share$0.8
Beta0.55
Outstanding Shares12,625,000

Return

Return on Equity21.20%ROE
Return on Assets11.38%
Return on Invested Capital20.46%

Valuation & Multiples

P/E Ratio17.27P/E Ratio
PEG-28.43PEG
Price to Sales0.52Price to Sales
Price to Book Ratio4.16Price to Book Ratio
Enterprise Value to Revenue0.47
Enterprise Value to EBIT11.28
Enterprise Value to Net Income13
Total Debt to Enterprise0.11
Debt to Equity0.31Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 6, 2026
EPS Estimate
$0.16
Average shareholder expectation
Revenue Estimate
$47.77 M
Average shareholder expectation

Next Earnings Call

Expected Date
September 3, 2026
EPS Estimate
$0.15
Average shareholder expectation
Revenue Estimate
$43.97 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.2531 25.31%
Total Calls104,700 Infinity%
Total Puts26,500 43.38%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %60.00% 0.08%
Total Invested$32.77M 30.04%
Investors Holding105 6.00%

ESG Score

No data

About Lifevantage Corporation

CEO: Darren Jensen

LifeVantage Corporation is a pioneer in Nutrigenomics - a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary suppl...